Last edition
News about "Short Bowel Syndrome (SBS) treatment"
Hanmi Signs Licensing Agreement with Lilly for Sonefpeglutide
Hanmi has signed a licensing agreement with Lilly for sonefpeglutide (LAPSGLP-2 analog), granting rights to develop and commercialize the investigational therapy across multiple indications.
Short Bowel Syndrome (SBS) Treatment | 03/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members